Medical Research from Mars Can Fail Patients from Venus
BIOtech Now Jim Greenwood Historically, federal dollars inadvertently flowed to medical research with a disproportionate focus on men’s health. There are several […]
BIOtech Now Jim Greenwood Historically, federal dollars inadvertently flowed to medical research with a disproportionate focus on men’s health. There are several […]
BIOtech Now Theresa Brady The rapid pace of scientific discovery, FDA approvals, commercialization of medicines held long in pipelines, and numerous IPOs […]
BIOtech Now Andrew Segerman Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit managers (PBMs), for […]
BIOtech Now Andrew Segerman The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in health and social […]
BIOtech Now Theresa Brady Congress, the Food and Drug Administration (FDA), drug developers, researchers and patient groups have all recognized the contribution […]
BIOtech Now Jeremy Isenberg Emerging technologies are disrupting the healthcare system as we know it—none more so than artificial intelligence (AI), which […]
BIOtech Now Phyllis Arthur August marks National Immunization Awareness Month – a time to take inventory on where we stand, and recognize […]
BIOtech Now Andrew Segerman National Immunization Awareness Month might be coming to a close, but it’s important to continue helping people understand […]
BIOtech Now Andrew Segerman IQVIA — a nonpartisan health care research firm — is out with troubling new data showing a direct […]
BIOtech Now Andrew Segerman A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine what patients pay […]
BIOtech Now Jim Greenwood BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the case for the […]
BIOtech Now Andrew Segerman Writing for The Hill, Dr. Robert Kadlec, Assistant Secretary for Preparedness and Response for the U.S. Department of […]
BIOtech Now Andrew Segerman In a recent piece for Forbes, Pfizer’s Chairman and CEO Ian Read highlights the significant economic value that […]
BIOtech Now Brian Newell It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators for the rising […]
BIOtech Now Andrew Segerman Writing last week for Morning Consult, BIO President and CEO Jim Greenwood proposed several policy ideas for Washington […]
BIOtech Now Trevor Roberts Sticker shock at the pharmacy counter is becoming increasingly more common for patients across the nation. But with […]
BIOtech Now Andrew Segerman Opioid abuse and addiction in America continues to ravish communities, families, and individuals across the nation. With an […]
BIOtech Now Jim Greenwood The facts continue to show that, when it comes to prescription drug costs, the country is heading in […]
BIOtech Now Daniel Seaton Later this morning, the House Energy and Commerce Committee will hold a hearing to examine the rampant abuse […]
BIOtech Now Daniel Seaton Today, 83 percent of children with cancer survive, compared to just 58 percent in the mid-1970s. Hepatitis C, […]